Today announced that on Fri April 16th.

Catalyst Pharmaceutical Companions’ vigabatrin data to be presented in 41st ASAM conference Catalyst Pharmaceutical Partners, Inc. today announced that on Fri April 16th, Eugene C. Dr. Somoza was the Coordinating Principal Investigator for the trial and can discuss data from Catalyst’s U.S. Stage II trial evaluating CPP-109, Catalyst’s form of vigabatrin, to treat cocaine addiction.’.Jeff Williams will stay the Chief Executive Officer and Chairman of the combined firm. Together we can make real benefits in overcoming the gaps in procedure that make traditional CROs inefficient, said Chris Porter, COO, Clinipace Worldwide. We talk about a long-term strategy of creating a more effective and effective technology-amplified remedy for our lifestyle sciences clients all over the world. .

PRESS RELEASE DUBLIN, Ohio, March 9, 2015— Cardinal Health today announced an agreement with Pathways to Achievement Physicians, LLC, that will help health system executives and hospital site managers increase efficiencies and cost-performance across hospital-owned physician procedures.

Random entries

Other entries from category "cosmetology":